DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 7, 2016, reports the full-year 2015 financial results for DBV Technologies S.A., a clinical-stage specialty biopharmaceutical company. The company focuses on developing Viaskin, a skin patch technology for treating food allergies (specifically milk and peanut). The 2015 consolidated financial statements have undergone audit procedures, though the final audit report issuance was pending at the time of filing.
Key Financial Metrics (2015 vs. 2014)
| Metric (in millions EUR) | 2014 | 2015 |
|---|---|---|
| Total Income | 4.8 | 6.2 |
| Research and Development Expenses | (21.1) | (34.2) |
| General and Administrative Expenses | (8.1) | (16.9) |
| Operating Loss | (24.6) | (45.6) |
| Net Loss | (24.0) | (44.7) |
| EPS (EUR per share) | (1.49) | (2.08) |
| Net Cash Flow from Operating Activities | (20.6) | (26.8) |
| Net Cash Flow from Financing Activities | 96.8 | 241.0 |
| Net Cash Flow | 75.2 | 208.9 |
| Cash and Cash Equivalents (Closing) | 114.6 | 323.4 |
Material Changes
- Revenue Growth: Total income increased 29.5% to €6.2 million, driven primarily by research tax credits and government subsidies. Commercial sales of the Diallertest product decreased to €202k due to the termination of a commercial partnership in late 2015.
- Expense Increases: R&D expenses rose 61.9% to €34.2 million due to expanded pre-clinical and clinical activities and hiring. G&A expenses surged 108% to €16.9 million, attributed to increased headcount, NASDAQ listing audit fees, and Sarbanes-Oxley compliance costs.
- Liquidity Position: Net cash from financing activities jumped to €241.0 million, primarily from a July 2015 underwritten public offering of American Depositary Shares. Closing cash balances more than doubled to €323.4 million.
Outlook, Risks, and Management Commentary
Management highlighted the clinical progress of Viaskin Peanut and Viaskin Milk, noting that the Viaskin Peanut program has received Fast Track and Breakthrough Therapy designations from the FDA. The company emphasized that historical preclinical and clinical results may not predict future outcomes. Forward-looking statements are subject to substantial risks, including uncertainties in clinical trials, regulatory approvals, and the commercial potential of product candidates. The filing explicitly states that the company undertakes no obligation to update these statements.
Investor Verification Checklist
- Verify the final issuance of the 2015 statutory audit report.
- Confirm the status and timeline of the Viaskin Peanut and Milk clinical trials.
- Assess the sustainability of government subsidies and tax credits as a revenue source.
- Review the burn rate relative to the €323.4 million cash position to estimate runway.
- Monitor regulatory updates regarding the FDA Fast Track and Breakthrough Therapy designations.